

# 1 ***serosim*: an R package for simulating serological survey data arising** 2 **from vaccination, epidemiological and antibody kinetics processes**

3  
4 **Arthur Menezes<sup>\*1</sup>, Saki Takahashi<sup>2</sup>, Isobel Routledge<sup>3</sup>, C. Jessica E. Metcalf<sup>1,4</sup>, Andrea L.**  
5 **Graham<sup>1,5</sup>, James A. Hay<sup>\*6,7</sup>**

6  
7 <sup>1</sup> Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA.

8 <sup>2</sup> Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,  
9 USA.

10 <sup>3</sup> Department of Medicine, University of California San Francisco, San Francisco, CA, USA.

11 <sup>4</sup> Princeton School of Public and International Affairs, Princeton University, Princeton, NJ, USA.

12 <sup>5</sup> Santa Fe Institute, Santa Fe, NM, USA.

13 <sup>6</sup> Big Data Institute, University of Oxford, Oxford, United Kingdom.

14 <sup>7</sup> Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health,  
15 Boston, MA, USA.

16  
17 \* Corresponding authors

18 E-mail: [am83@princeton.edu](mailto:am83@princeton.edu) ; [james.hay@ndm.ox.ac.uk](mailto:james.hay@ndm.ox.ac.uk)

## 21 **Abstract**

22 *serosim* is an open source R package designed to aid inference of serological surveys, by  
23 simulating data arising from user-specified vaccine and infection-generated antibody kinetics  
24 processes using a random effects model. Serological surveys are used to assess population  
25 immunity by directly measuring individuals' antibody titers. They uncover locations and/or  
26 populations which are susceptible and provide evidence of past infection or vaccination to help  
27 inform public health measures and surveillance. Both serological surveys and new analytical  
28 techniques used to interpret them are increasingly widespread. This expansion creates a need  
29 for tools to simulate serological surveys and the processes underlying the observed titer values,  
30 as this will enable researchers to identify best practices for serological survey design, and provide  
31 a standardized framework to evaluate the performance of different inference methods. *serosim*  
32 allows users to specify and adjust model inputs representing underlying processes responsible  
33 for generating the observed titer values like time-varying patterns of infection and vaccination,

34 population demography, immunity and antibody kinetics, and serological survey sampling design  
35 in order to best represent the population and disease system(s) of interest. This package will be  
36 useful for planning sampling design of future serological surveys, understanding determinants of  
37 observed serological data, and validating the accuracy and power of new statistical methods.

38

## 39 **Author Summary**

40 Public health researchers use serological surveys to obtain serum samples from  
41 individuals and measure antibody levels against one or more pathogens. When paired with  
42 appropriate analytical methods, these surveys can be used to determine whether individuals have  
43 been previously infected with or vaccinated against those pathogens. However, there is currently  
44 a lack of tools to simulate realistic serological survey data from the processes determining these  
45 observed antibody levels. We developed *serosim*, an open source R package which enables  
46 users to simulate serological survey data matching their disease system(s) of interest. This  
47 package allows users to specify and modify model inputs responsible for generating an  
48 individual's antibody level at various levels, from the within-host processes to the observation  
49 process. *serosim* will be useful for designing more informative serological surveys, better  
50 understanding the processes behind observed serological data, and assessing new serological  
51 survey analytical methods.

52

53

54

55

56

57

58

59

60

## 61 **Introduction**


62 Serological surveys, also known as serosurveys, measure individual biomarker quantities,  
63 namely antibody titers, across populations to help uncover important hidden epidemiological  
64 variables such as susceptibility and past epidemic and vaccination trends[1]. These hidden  
65 variables are required to predict and prevent outbreaks at the population level, and while they  
66 may be indirectly inferred via vaccination coverage and incidence data, this inference is subject  
67 to inaccuracies since vaccination coverage does not directly translate to individuals immunized  
68 and incidence data is often underreported and incomplete[2–8]. Properly designed and analyzed  
69 serological surveys mitigate these issues by providing direct measures of population level  
70 immunity[9,10].

71  
72 The optimal design and interpretation of serological surveys depends on many factors,  
73 including the antibody class or biomarker measured, the age at which individuals are sampled,  
74 the frequency of sampling, the assay used for analysis, etc[1,6]. These features yield different  
75 insights into processes associated with the immune landscape (e.g., who is and isn't protected  
76 from infection or disease by pre-existing immunity): cross-sectional serosurveys provide a  
77 snapshot of the seropositivity rates and therefore the proportion of individuals protected against  
78 a pathogen (which might be used to target vaccination campaigns[1,10]), while longitudinal  
79 serosurveys can also yield estimates of seroconversion events between sampling times, and  
80 antibody waning rates[11]. Difficulties arise in serosurvey design and analysis as researchers  
81 strive to achieve a representative sample of the target population to make generalizations at larger  
82 scales, or attain the right temporal sampling density to capture parameters of interest like waning  
83 rates[6].

84  
85 Serosurvey analysis is complicated by the various unobserved and complex  
86 immunological and epidemiological processes which generate an individual's observed biomarker

87 quantity. Statistical and mathematical models designed to interpret observed antibody titers, or  
88 biomarkers more generally, range from simple measures of seroconversion or seropositivity (e.g.,  
89 serocatalytic models [12,13]) to complex models of within- and between-host processes (e.g.,  
90 hierarchical models of antibody kinetics [14–16]). All of these approaches aim to make useful  
91 inferences about exposures and immunity without exhaustively capturing all features of the true  
92 data-generating process[8,12,17]. More realistic models describe the link between observed  
93 biomarker measurements and latent infection and vaccination states (Fig 1) and can be used to  
94 calculate the likelihood of an infection, and estimate antibody kinetics parameters (see Supporting  
95 Text 1.2 of Hay et al., 2020 for a full description) [14–16]. These models typically describe key  
96 features of the multi-level data-generating process: the population-level processes which govern  
97 rates of exposure; the within-host processes which determine immunity and latent antibody  
98 kinetics; and the observation process which dictates the relationship between observed and true  
99 biomarker quantities (Fig 1). Additionally, hierarchical Bayesian models can help account for the  
100 variability from multiple epidemiological processes which can improve our understanding of  
101 heterogeneities driving disease dynamics[14,15].

## Directed acyclic graph representation of the full model



102  
 103 **Fig 1. Directed acyclic graph representation of the full serosim model.** Each model level is shown  
 104 within a box with stochastic dependencies depicted by a solid arrow and deterministic dependencies by a  
 105 dashed arrow. Parameters/latent states of interest are depicted within the blue circles while the red square  
 106 represents the observed state. The unobserved processes level (latent states) contains the epidemiological  
 107 model (exposure model and immunity model) and the antibody model while the observed processes level  
 108 contains the observation model. The probability of a successful exposure event  $x$  for individual  $i$  at time  $t$   
 109 ( $\phi_{i,t,x}$ ) is determined by the user-specified exposure and immunity models (1,2,3) while  $Z_{i,t,x}$  is the binary  
 110 state indicating whether individual  $i$  was infected or vaccinated by exposure event  $x$  at time  $t$  as determined  
 111 by a Bernoulli trial (4). The antibody model (5) specifies how the true quantity of biomarker  $b$  for individual  
 112  $i$  at time  $t$  ( $A_{i,t,b}$ ) is generated. Lastly, the observation model (6) specifies how the observed quantity of  
 113 biomarker  $b$  for individual  $i$  at time  $t$  ( $Y_{i,t,b}$ ) is generated as a probabilistic function of the true, latent  
 114 biomarker quantity  $A$ .

115  
 116  
 117

118           Although new analytical techniques have been developed to aid in the interpretation of  
119 serological surveys[9,13,15,16,18], there is a need for common frameworks to simulate observed  
120 serological data arising from complex hidden and unobserved epidemiological and immunological  
121 processes within different pathogen systems. By simulating synthetic datasets from different  
122 complex generative models where the true, full complexity of the data generating process is  
123 specified but not observable, such frameworks can be used to assess the performance and trade-  
124 offs of new analytical techniques. The *serosim* package allows users to simulate observed  
125 biomarker quantities arising from a user-specified set of between- and within-host processes.  
126 These simulations provide datasets to evaluate different statistical methods and study designs,  
127 allowing users to specify and adjust model inputs to best represent the population and disease  
128 system(s) of interest.

129

130 We envisage three main use cases for *serosim*:

- 131       • Plan serosurvey sampling strategies by simulating various observation processes (varying  
132           sample sizes, sampling frequency and assay characteristics) and analyzing the inferences  
133           that can be made given the quality of the generated data (e.g., power analyses).
- 134       • Uncover the underlying immunological and epidemiological mechanisms responsible for  
135           observed biomarkers (e.g., antibody titers) by comparing simulations under different  
136           models and parameter values to existing serological survey results.
- 137       • Generate synthetic serological data from complex, user-specified generative models to  
138           assess the performance and trade-offs of inference models.

139

140

141           Here, we explain the structure of the *serosim* package and its implementation. We then  
142 outline the components required for the main function, **runserosim**, explain their purpose and  
143 structure, outline useful tools available within *serosim* to aid in their construction and provide a

144 simple example case study. Additionally, we direct users to two additional case study vignettes,  
145 available in the package, structured in the same order as the following methods subsections to  
146 assist users in constructing the required simulation inputs under different contexts. Lastly, we  
147 demonstrate a simple use case for *serosim*; using simulation-recovery experiments to assess the  
148 sensitivity and specificity of different biomarker thresholds of seropositivity.  
149  
150  
151

## 152 1 Methods

153

### 154 Approach

155 *Serosim* allows users to define the data-generating process underpinning theoretical  
156 serosurvey data with maximum flexibility. To define the different stages of the simulation, we first  
157 consider what a generic, full likelihood and prior function would look like to estimate antibody  
158 kinetics and epidemiological parameters conditional on a set of observed biomarker quantities in  
159 a Bayesian framework (Equation 1, also see [15,19,20]). Each probabilistic term in this equation  
160 corresponds to a stochastic event in the simulation (though deterministic models may also be  
161 implemented in the same framework). There are a number of indices which must first be described  
162 (Table 1). Each individual is denoted  $i$ ,  $t$  denotes the discrete time period during which an  
163 exposure event or observation could take place and  $j$  denotes all time periods prior to  $t$ . Each  
164 biomarker which we are concerned with, either as latent quantities or observations are denoted  
165  $b$ , and may be stimulated by one or more exposure events denoted  $x$ . Each individual may be  
166 associated with a set of demographic information,  $D_i$  including a group identifier  $g$ .

167

168

$$P(A, Z, \Theta | Y) \propto \prod_{i=1}^n \left( \prod_{t \in t_i} P(Y_{i,t,b} | A_{i,t,b}, \Theta) \right) \prod_{j=j_{min}}^{j_{max}} P(A_{i,j,b} | Z_{i,j \leq t,x}, \Theta_i, D_i) P(Z_{i,j \leq t,x} | \Phi_{i,t,x}, Z_{i,j < t,x}, \Theta_i, D_i) P(\Phi_{i,t,x} | \lambda_{g,t,x}, \Theta_i, D_i) P(\lambda) P(D) P(\Theta) \quad (1)$$

169

170

171

172

173

174

175

176

177

178

179

180



181 **Table 1. Names and descriptions of the variables used in the *serosim* package.**

Variable	Name	Description
<b>Inputs</b>		
$i$	<u>I</u> ndividual	Unique individual identifier.
$t$	<u>T</u> ime	Time point at which an individual may be exposed or have a biomarker quantity calculated.
$x$	<u>E</u> xposure event	Identifier for each exposure event which can generate an immunological response in the model (e.g., infection with a SARS-CoV-2 variant or vaccination with a multivalent vaccine).
$b$	<u>B</u> iomarker	Identifier for the biomarker(s) boosted in response to a particular antigen present in the exposure event (e.g., pathogen-specific ELISA IgG titers, microneutralization titers etc.).
$g$	<u>G</u> roup	Group identifier, allowing group-specific force of infection and vaccination parameters (e.g., spatial structure).
$D$	<u>D</u> emography data	Additional demographic data which may impact the infection generation process, the immunity model and/or antibody kinetics (e.g., age-dependent antibody waning rates or vaccination schedule).
$\lambda$	Force of exposure (FOE)	Parameters for the exposure process model, ultimately used to generate a probability of infection or vaccination for a given time period $t$ .
$\Theta$	Antibody, immunity and observation model parameters	Parameters governing the within-host process models (e.g., how biomarker quantities change over time-since-infection and how immunity depends on past exposure events).
<b>Outputs</b>		
$\Phi$	Time varying probability of a successful exposure event	Probability of exposure (determined by the exposure model) multiplied by the probability of a successful exposure event defined as a measurable immunological response (determined by the immunity model).
$Z$	Exposure history array	Array of latent binary states (i.e., 0 or 1) representing the time points and exposure events that an individual has been infected or vaccinated at.
$A$	True biomarker quantity	True, latent biomarker quantity predicted by the antibody kinetics model prior to simulating the observation process.
$Y$	Observed biomarker quantity	Observed biomarker quantity assuming some observation process dictating the distribution of $Y$ as a function of $A$ .


183 *Serosim* combines the unobserved and observed processes which together contain three  
 184 different model levels (Fig 1, Table 2). The unobserved processes are composed of the  
 185 epidemiological model and antibody model. The epidemiological model contains the exposure  
 186 model  $h$  which will determine the probability that an individual  $i$  is exposed in an exposure event  
 187  $x$  and the immunity model  $m$  which will determine whether that exposure event is successful at  
 188 generating or boosting biomarker quantities given any relevant factors (e.g., vaccination schedule,  
 189 titer threshold required for protection, etc.). For the purpose of *serosim*, exposure events  $x$  are  
 190 defined as any event which leads to biomarker  $b$  production, irrespective of any associated  
 191 disease onset. This definition of exposure allows users to track vaccination, infection and re-  
 192 infection events simultaneously but separately alongside the biomarkers produced as a result of  
 193 different exposure events. Biomarkers  $b$  can represent antibodies binding the entire virus or a  
 194 specific epitope depending on the user's preference and assay characteristics. Users will define  
 195 the biomarker(s) affected by each exposure type within the exposure-to-biomarker map which  
 196 follows a many-to-many relationship and tells the antibody model  $f$  which biomarker(s) (e.g., which  
 197 specific antibody titers) will get boosted and tracked after each exposure event  $x$ , allowing for  
 198 simulation of a diverse range of pathogen systems [10,18,21–24] (Fig 2).

199 **Table 2. *serosim* framework.**

Unobserved processes		Observed processes	
Epidemiological model		Antibody model	Observation model
1. <b>Exposure model (<math>h</math>):</b> will determine the probability that an individual is exposed to an exposure event which can be any event which leads to biomarker production	2. <b>Immunity model (<math>m</math>):</b> determines whether an exposure event is successful conditional on what the actual exposure is (vaccination, infection or re-infection) and the relevant factors	3. <b>Antibody model (<math>f</math>):</b> tracks antibody kinetics, or more broadly biomarker kinetics for each biomarker produced from successful exposure events	4. <b>Observation model (<math>q</math>):</b> indicates how observed biomarker quantity $Y$ are generated as a probabilistic function of the true, latent biomarker quantity $A$

200

## Exposure to biomarker mapping example scenarios



201  
 202 **Fig 2. Exposure to biomarker mapping example scenarios.** The biomarker map specifies the exposure  
 203 events  $x$  and biomarkers  $b$  of interest for the user's simulation. Exposure events  $x$  are defined as any event  
 204 which leads to biomarker production. Biomarkers  $b$  can represent antibodies against the entire virus, a  
 205 specific epitope or a specific antibody class depending on the user's preference and assay characteristic.  
 206 Here, we provide various examples of biomarker maps to illustrate the flexibility over the data-generating  
 207 process provided to the user.

208  
 209  
 210 We distinguish between exposure event  $x$  and biomarker  $b$  to allow both a single exposure  
 211 event to boost multiple biomarkers (e.g., antibody titers of multiple antigens following a multivalent  
 212 vaccine of a single infection) and also to allow the same biomarker to be boosted by multiple  
 213 exposure events (e.g., both vaccination and natural infection boosting the same biomarker) (Fig  
 214 2). This distinction also allows the user to assign different biomarker kinetics parameters (e.g.,  
 215 boosting and waning rates) to different exposure events. Biomarkers can also represent different  
 216 antibody classes (e.g. IgM and IgG) allowing users to assign different time signatures to  
 217 biomarkers tracked within the simulation. Users can also incorporate multi-dose vaccines given

218 at different ages by breaking up the vaccine exposure events into multiple exposure events for  
219 each vaccine dose. This will allow users to set different age restrictions and antibody kinetics  
220 parameters for each dose. Although a majority of *serosim* use cases will track antibodies as  
221 biomarkers, we use “biomarker” as a broader term to accommodate newer technologies emerging  
222 which don’t measure antibodies directly but rather measure a proportional biomarker[25]. For the  
223 purposes of this paper and example vignettes in *serosim*, the term biomarker and antibody are  
224 used interchangeably.

225

226 The immunity model  $m$  then determines whether that exposure event  $x$  is successful  
227 conditional on what the actual exposure is (vaccination, infection or re-infection) and any relevant  
228 factors, discussed later. The antibody model  $f$  tracks antibody kinetics, or more broadly biomarker  
229 kinetics for each biomarker produced from successful exposure events through time. The  
230 exposure, immunity and antibody models make up the complex, unobserved processes  
231 responsible for generating an individual’s true biomarker quantity  $A$  (Fig 1, Table 2).

232

233 The second and final level contains the observation model  $q$  which specifies the  
234 serological survey observation process to indicate how observed biomarker quantity  $Y$  are  
235 generated as a probabilistic function of the true, latent biomarker quantity  $A$  (Fig 1, Table 2).  
236 Users can also specify the sampling design (time, frequency and sample size) for the serosurvey  
237 and any assay characteristics (sensitivity, specificity and detection limits). Although the  
238 underlying, unobserved model inputs can be varied, *serosim* ultimately produces the same output:  
239 observed biomarker quantities  $Y$ .

240

241

242

243

244

245

## 246 **Implementation**

247       The *serosim* package is written in the R programming language. Package dependencies  
248 are `ggplot2`[26], `data.table`[27], `tidyverse`[28], `patchwork`[29] and `reshape2`[30]. All code is publicly  
249 available on GitHub (<https://github.com/AMenezes97/serosim>). For the following sections  
250 describing the code, typewriter font refers to function arguments while bold font refers to R  
251 functions.

252

253       The core of *serosim* is contained within the **runserosim** function, where users specify  
254 each of the required model inputs (S1 Table). This function must take a number of default  
255 arguments described in S1 Table, but additional optional arguments may also be provided for  
256 user-written functions. This gives the user flexibility to tailor their own settings, models and  
257 parameters to their population and disease system(s) of interest. For example, if the user wishes  
258 to model a fully immunizing pathogen system like measles they can specify an immunity model  
259 which only allows individuals with biomarker quantity (e.g. IgG antibody titer) below a specified  
260 threshold to become infected and restrict re-infections. If the user wishes to model a pathogen  
261 system with multiple infection events and cross-reactivity between different pathogen strains like  
262 influenza then they would specify an immunity model where the probability of infection is  
263 conditional on an individual's biomarker quantity (e.g., antibody titer) from any cross-reacting  
264 antibodies and allows for multiple infection events. These models would be specified within their  
265 respective **runserosim** argument and any additional arguments needed will be passed at the end  
266 of **runserosim**. Users are not constrained to data structures of particular dimensions or types,  
267 and thus all of the model components can be extended to any desired level of complexity.

268

269       The *serosim* package includes tools to help the user generate the necessary inputs for the  
270 **runserosim** function, discussed below in their respective sections. Additionally, there are some  
271 ready-to-use model functions built into the *serosim* package for convenience (S4-8 Tables). If any

272 of these model functions meet the needs of the user's disease system and simulation model, the  
273 user simply has to specify the desired function as its corresponding argument within the  
274 **runserosim** function. These ready-to-use functions also provide a helpful framework if users wish  
275 to create their own function or make modifications to an existing function.

276

277 The following subsections 1.1-1.7 step through the process of building and specifying the  
278 required inputs for a simulation presented in the same order as Figure 3. We have also integrated  
279 the README example available within the package within this description.

280

281

282

283

284

285

286

287

## Initial simulation inputs

- 1) Simulation settings    2) Population demography    3) Exposure to biomarker mapping



simulation start and end time



population size & relevant demography information (D)



Inputs	Model	Outputs																
<p><b>4) Exposure model (<i>h</i>)</b> FOE force of exposures (<math>\lambda</math>) relevant demography information (D)</p>	$P(E_{i,t,x} = 1) = h(\lambda_{g,t,x}, D_i)$	<p>force of exposures (<math>\lambda</math>) vs time</p>																
<p><b>5) Immunity model (<i>m</i>)</b> immunity against infection (<math>\theta</math>) infection → biomarker vaccination → biomarker relevant demography information &amp; vaccination schedule (D)</p>	$P(Z_{i,t,x}=1   E_{i,t,x}=1) = m(Z_{i,j<t}, \theta_i, D_i)$ $\varphi_{i,t,x} = P(Z_{i,t,x}=1   E_{i,t,x}=1)P(E_{i,t,x}=1)$ $Z_{i,t,x} \sim \text{Bernoulli}(\varphi_{i,t,x})$	<p>Exposure history (Z)</p> <table border="1"> <tr> <td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td> </tr> <tr> <td>0</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td> </tr> </table> <p>infection history vaccination history</p>	0	0	0	1	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	1	0	0	0	0											
0	1	0	0	0	0	0	0											
<p><b>6) Antibody model (<i>f</i>)</b> infection → biomarker vaccination → biomarker boost~N(mean, sd) biomarker kinetics wane~N(mean, sd) parameters (<math>\theta</math>) biomarker kinetics model (<i>f</i>) exposure history (Z) vaccination history relevant demography information (D)</p> <table border="1"> <tr> <td>0</td><td>0</td><td>0</td><td>1</td> </tr> <tr> <td>0</td><td>1</td><td>0</td><td>0</td> </tr> </table>	0	0	0	1	0	1	0	0	$A_{i,t,b} = f(Z_{i,j \leq t,x}, \theta_i, D_i)$	<p>True biomarker quantity (A)</p>								
0	0	0	1															
0	1	0	0															
<p><b>7) Observation model (<i>q</i>)</b> observation time(s) and sample size time=120 assay characteristics (sensitivity, specificity, detection limits)</p>	$Y_{i,t,b} \sim q(A_{i,t,b}, \theta)$	<p>Observed biomarker quantity (Y)</p>																

### KEY

*i* = individual

*t* = time

*j* = time before *t*

*x* = exposure event

*b* = biomarker

*g* = group

$\lambda$  = force of exposure

D = demography information

*h* = exposure model

*m* = immunity model

*f* = antibody model

*q* = observation model

$\theta$  = antibody, immunity and observation model parameters

$\varphi$  = exposure probability

Z = exposure history

A = true biomarker quantity

Y = observed biomarker quantity

289 **Fig 3. Required inputs, models and subsequent outputs from the main *serosim* function,**  
290 ***runserosim*.** In order to build a simulation with *serosim*, users must follow the 7 steps outlined here and in  
291 the methods section to specify the required inputs and models for ***runserosim***. Steps 1-3 specify initial  
292 simulation inputs while steps 4-7 specify the bulk of the unobserved and observed processes. For steps 4-  
293 7, we outline the user-specified inputs in the left column which are used for the user-specified models as  
294 depicted by the sampling statements in the middle column. Lastly, the generated outputs produced once  
295 the simulation is complete are depicted in the right column.

296  
297

## 298 **1.1 Simulation settings**

299 Here, the user specifies the start and end time for the simulation. The model will simulate  
300 from the initial time point to the final time point in increments of one unless specified otherwise.  
301 Note that these are arbitrary time steps selected by the user which will need to be scaled to the  
302 right time resolution to match any time-based parameters used in the model (e.g., antibody  
303 waning rates). In this example, we simulated a ten year period at the monthly timescale by setting  
304 the start and end time points to 1 and 120.

305

## 306 **1.2 Population demography**

307 Users will specify the population size and have the option of specifying any population  
308 demographic elements of interest and relevance for the subsequent models like an individual's  
309 socioeconomic status, nutritional status, sex, group, birth time, etc... via the `demography` tibble  
310 [31]. See S1.1 Text for information on how to use the **`generate_pop_demography`** function to  
311 build your `demography` tibble.

312

313 For this example, we simulate a population with 100 individuals and we are not interested  
314 in tracking any demographic information other than an individual's birth time. We will use the  
315 **`generate_pop_demography`** function to simulate random birth times and create the  
316 `demography` tibble needed for ***runserosim***.

317

318



### 319 **1.3 Exposure to biomarker mapping**

320 Here, users specify the relationship between exposure event  $x$  and biomarker(s)  $b$  (Fig 2).  
321 This example assumes one circulating pathogen responsible for a natural infection exposure  
322 event ( $exposure\_ID=ifxn$ ) and one vaccine exposure event ( $exposure\_ID=vacc$ ) both of which will  
323 boost the same biomarker ( $biomarker\_ID=lgG$ ) (S1 Fig). **runserosim** requires that exposure and  
324 biomarker IDs are numeric so we will use the **reformat\_biomarker\_map** function to create a new  
325 version of the biomarker map (S1.2 Text, S1 Fig). Users can go directly to the numeric version if  
326 they wish (S1 Fig).

327

### 328 **1.4 Exposure model**

329 Here, users specify any known information on force of exposure for all exposure events  $x$   
330 and the first part of the epidemiological model, the exposure model  $h$ . We distinguish between  
331 the probability of exposure (determined by the exposure model) and the probability of an exposure  
332 event generating a successful immunological response (determined by the immunity model), so  
333 that the latter can take into account important immunological and epidemiological considerations.  
334 For example, an individual's probability of exposure to exposure event  $x$  which is specified at the  
335 population level might be different from their probability of becoming immunized conditional on  
336 what the actual exposure event is (vaccination, infection or re-infection) and any relevant factors  
337 (e.g. age, number of past vaccinations, current titer level, etc).

338

339 The force of the exposure event ( $foe\_pars$ ) argument is typically a three-dimensional  
340 array indicating the force of exposure for each exposure event in each group (if groups are  
341 specified within `demography`) in each time period, though this object can also be another data  
342 type for more complex models. Since exposure events can also be vaccination events, we use  
343 force of exposure (FOE) rather than force of infection. If there is only one group specified then all

344 individuals will be under the same force of exposure parameter and dimension 1 of `foe_pars`  
345 will contain just one row.

346  
347 Although this package does not include a suite of complex transmission models (e.g.,  
348 complex Susceptible-Infected-Recovered models), users can incorporate the outputs of their own  
349 preferred transmission model within **runserosim**. In `foe_pars`, users can input the force of  
350 infection generated from their transmission model into the `exposure_id` dimension associated  
351 with natural infection events. Users can also use the optional `exposure_histories_fixed`  
352 argument in **runserosim** to include prespecified information on an individual's exposure history if  
353 known (See S2.1 Text and S2 Fig).

354  
355 The force of exposure (`foe_pars`) array is called by the exposure model function which  
356 will determine the probability that an individual is exposed. The exposure model, specified by the  
357 `exposure_model` argument within **runserosim**, allows the user to determine which factors are  
358 relevant for an individual's probability of exposure. The exposure model can vary in complexity  
359 with simpler versions calculating the probability of exposure by just taking the exposure event's  
360 population level force of exposure into account and with more complex versions providing a  
361 functional transformation of the population level force of exposure given an individual's  
362 demographic information specified within `demography`. For example, an individual can be in a  
363 group (e.g., a location) where the force of exposure is 0.5 but their socio-economic status is high  
364 which might reduce their probability of exposure given that the disease is circulating less in that  
365 socio-economic class. See S4 Table for more information on the ready-to-use exposure models  
366 included within the *serosim* package. The exposure model is given by:

367 
$$P(E_{i,t,x} = 1) = h(\lambda_{g,t,x}, D_i) \quad (2)$$

368 where  $P(E_{i,t,x} = 1)$ , the probability of an exposure  $E$  for individual  $i$  at time  $t$  to exposure event  
369  $x$ , is a function  $h$  of parameters specified within the **exposure model**, namely  $\lambda_{g,t,x}$  which  
370 represents the force of the exposure (FOE) at time  $t$  in group  $g$  from exposure event  $x$ .  $D_i$   
371 represents relevant demographic information of individual  $i$ , which may be used to modulate the  
372 force of exposure term (e.g., if there are differences in FOE by age).

373  
374 For simplicity in this example, we assumed a constant force of exposure for exposure  
375 event one representing natural infection at  $\lambda_{1,t,1} = 0.01$  and for exposure event two  
376 representing vaccination at  $\lambda_{1,t,2} = 0.1$  for all  $t$ . Since we did not specify different groups for  
377 our individuals within demography, all individuals will automatically be assigned group one within  
378 **runserosim**. Therefore, we only need one row for dimension one in `foe_pars`. Dimension two  
379 of `foe_pars` represents the total simulation time so there are 120 columns (where the first  
380 column is time step one, second column is time step two, etc.) and dimension three is for each  
381 exposure event. Similarly, we specified a simple exposure model which calculates the probability  
382 of exposure directly from the force of exposure at that time step. In this selected model, the  
383 probability of exposure ( $1 - e^{-\lambda}$ ) depends only on the force of exposure ( $\lambda$ ) at that time.

384

385

## 386 1.5 Immunity model

387 The immunity model  $m$ , specified by the `immunity_model` argument, will determine  
388 whether an exposure event is successful in generating an immunological response given any  
389 relevant factors specified by the user. The immunity model can vary in complexity with simpler  
390 versions assuming all exposures are successful and with more complex versions taking into  
391 account what the exposure event is (e.g., a vaccination event or natural exposure to a pathogen),  
392 an individual's past exposure history, current biomarker quantity and any relevant demography  
393 data. The immunity model is given by:

$$394 \\ 395 P(Z_{i,t,x} = 1 | E_{i,t,x} = 1) = m(Z_{i,j<t}, \Theta_i, D_i) \quad (3)$$

396 where  $P(Z_{i,t,x} = 1 | E_{i,t,x} = 1)$ , the probability of successful infection or vaccination of  
397 exposure event  $x$  given an exposure, is a function  $m$  of parameters specified within the immunity  
398 model.  $Z_{i,j<t}$  represents all successful infection/vaccination events at each timepoint  $j$  prior to  
399 time  $t$  (i.e., the exposure history),  $\Theta_i$  represents the immunity model parameters and  $D_i$   
400 represents any relevant demographic data. Note that  
401  $P(Z_{i,t,x} = 1 | E_{i,t,x} = 0) = 0$  and  $P(Z_{i,t,x} = 0 | E_{i,t,x} = 0) = 1$ .

$$402 \\ 403 \phi_{i,t,x} = P(Z_{i,t,x} = 1 | E_{i,t,x} = 1)P(E_{i,t,x} = 1) \quad (4)$$

404  
405 where  $\phi_{i,t,x}$  is the probability of successful exposure by exposure type  $x$  for individual  $i$  at time  $t$   
406 given the probability of exposure  $E_{i,t,x}$  as determined by the exposure model  $h$  and the  
407 probability of a successful exposure event  $Z_{i,t,x}$  as determined by the immunity model  $m$ .

$$408 \\ 409 Z_{i,t,x} \sim \text{Bernoulli}(\phi_{i,t,x}) \quad (5)$$

410  
411 where  $Z_{i,t,x}$  is the binary state indicating whether individual  $i$  was infected or vaccinated by  
412 exposure type  $x$  at time  $t$  as determined by a Bernoulli trial.

413 Users can incorporate immunity from prior infection or vaccination and add limits to  
414 vaccine exposure events to prevent vaccinations after a completed series or before an individual  
415 is eligible. See S5 Table for more information on the ready-to-use immunity models included  
416 within the *serosim* package. Any immunity model parameters  $\Theta$  needed for the immunity model  
417 can be specified within `model_pars`.

418  
419 For this example, we selected a simple immunity model where the probability of a  
420 successful exposure event is only conditional on the total number of previous exposure events.  
421 With this model, the probability of successful vaccination exposure depends on the number of  
422 vaccines received prior to time  $t$  ( $j \leq t$ ) and age at time  $t$ , while the probability of successful infection  
423 is dependent on the number of infections prior to time  $t$  ( $j \leq t$ ). We set both the maximum number  
424 of successful vaccination and natural infection events to one and age of vaccine eligibility starting  
425 at nine months old.

426  
427

## 428 **1.6 Antibody model and model parameters**

429 The antibody model  $f$ , specified by the `antibody_model` argument, is used to track  
430 antibody kinetics, or more broadly biomarker kinetics for each biomarker produced following  
431 successful exposure events given the biomarker kinetics model parameters specified in  
432 `model_pars` and any relevant demography data specified in `demography`. Here, users can  
433 specify their preferred model to represent the antibody kinetics process.

434

435 The antibody model is formulated to capture the possibility of a probabilistic relationship  
436 between exposure history, demography and model parameters with true biomarker quantities.  
437 However, in most cases the user will likely assume that biomarker quantity is a deterministic  
438 function of exposure history, demography and model parameters. In the deterministic case, latent  
439 biomarker quantity  $A$  for individual  $i$  at time  $t$  for biomarker  $b$  given that individual's vector of latent  
440 infection states  $\mathbf{Z}_i$ , antibody model parameters  $\Theta_i$  and relevant demographic information  $D_i$  can  
441 be generically described by:

$$442$$
$$443 \quad A_{i,t,b} = f(\mathbf{Z}_{i,j \leq t,x}, \Theta_i, D_i) \quad (6)$$

444 where  $A_{i,t,b}$ , the true quantity of biomarker  $b$  for individual  $i$  at time  $t$ , is described by a function  
445  $f$  conditional on parameters specified within the **antibody model**, including the  
446 infection/vaccination history for individual  $i$  for all exposure events which occurred prior to time  $t$   
447 ( $\mathbf{Z}_{i,j \leq t,x}$ ), the antibody model parameters ( $\Theta_i$ ) and any relevant demography data  $D_i$ .

448

449 The model parameters tibble, `model_pars`, specifies any parameters needed for the  
450 antibody model. Like the exposure and immunity models, the antibody model can vary in  
451 complexity depending on the user's preferences. For example, users could implement an explicit  
452 model of antibody secreting B cells or a biphasic boosting-waning model [32–34].

453

454 The last component of the antibody model layer is the **draw\_parameters** function which  
455 indicates how parameters  $\Theta$  for the antibody model are simulated from `model_pars`. Here, users  
456 can either assume a fixed effects or random effects model. A fixed effects model would assume  
457 all individuals are governed by the same set of parameters while the random effects model  
458 assumes each individual has their own unique set of parameters  $\Theta$  drawn from `model_pars`

459 allowing for individual- and group-level differences in antibody kinetics. See S6 and S7 Tables for  
460 more information on the ready-to-use antibody models and **draw\_parameters** functions included  
461 within the *serosim* package. The antibody model, model parameters tibble (`model_pars`) and  
462 **draw\_parameters** function must be structured in agreement with each other. The model  
463 parameters tibble must contain all of the necessary information needed for the **draw\_parameters**  
464 function to simulate all required variables in the antibody model.

465  
466 For this example, we selected a monophasic boosting-waning antibody model where  
467 parameters are drawn randomly from a distribution (e.g., see simple hierarchical boosting-waning  
468 model with individual heterogeneity for *Salmonella* infection [35]). This antibody model assumes  
469 that for each exposure there is a boost and boost waning parameter drawn randomly from a  
470 distribution with mean and standard deviation specified within `model_pars` (Table 3).

471  
472 **Table 3. `model_pars` parameters needed for a monophasic boosting-waning**  
473 **antibody model with random effects**

exposure_ID	biomarker_ID	name	mean	sd	distribution
ifxn	IgG	boost	4	2	log-normal
ifxn	IgG	wane	0.0033	.0005	log-normal
vacc	IgG	boost	2	1	log-normal
vacc	IgG	wane	0.0016	.0005	log-normal

474  
475  
476  
477  
478  
479  
480  
481  
482  
483

## 484 1.7 Observation model

485 The observation model  $q$ , specified by `observation_model`, along with  
486 `observation_times` are the last required parts of the simulation which specifies the serological  
487 survey observation process (Table 2). Here, users can indicate how observed biomarker  
488 quantities  $Y$  are generated as a probabilistic function of the true, latent biomarker quantity  $A$ . The  
489 observation model is given by:

$$490 Y_{i,t,b} \sim q(A_{i,t,b}, \Theta) \quad (7)$$

491 where  $Y_{i,t,b}$ , the observed quantity of biomarker  $b$  for individual  $i$  at time  $t$ , is a function  $q$   
492 specified by the observation model which specifies which distribution to draw the observed  
493 quantity where the true biomarker quantity  $A_{i,t,b}$  is the mean and the  $\Theta$  includes the standard  
494 deviation as well as any parameters governing assay specificity and sensitivity.

495

### 496 1.7a Assay characteristics

497 To match their assay of choice, users can incorporate assay detection limits like lower  
498 bounds, upper bounds, and assay output (discrete vs. continuous titers) within  
499 `observation_model` (S8 Table). Users can also incorporate assay sensitivity, specificity and  
500 assay noise within the `observation_model`. Noise can be easily added by sampling from a  
501 distribution with the true biomarker quantity,  $A$ , as the mean and the measurement error as the  
502 standard deviation such that  $Y_{i,t,b} \sim N(A_{i,t,b}, \Theta)$  where  $\Theta$  is the standard deviation specified within  
503 `model_pars` as the “`obs_sd`” parameter (Table 3). See S8 Table for more information on the  
504 ready-to-use observation models included within the *serosim* package. Any model parameters  
505 needed for the observation model can be combined into the `model_pars` tibble for convenience.

506 For this example, we selected an observation model which observes the latent biomarker  
507 quantity given a continuous assay with added noise (representing assay and sampling variation),  
508 no limits of detection and user specified assay sensitivity and specificity. We set the observation  
509 standard deviation to 0.25, the assay sensitivity to 85% and the assay specificity to 90%.



510 Therefore, 85% of true positive individuals will have their observed biomarker quantity sampled  
511 from a distribution with their true biomarker quantity as the mean and 0.25 as the standard  
512 deviation while the other 15% will be classified as a false negative with a reported biomarker  
513 quantity of 0. On the other hand, the model will accurately report 90% of true negative individuals'  
514 observed biomarker quantity as 0 with the remaining 10% becoming false positives with an  
515 observed biomarker quantity sampled from the range of observed biomarker quantities.

516

### 517 **1.7b Sampling design**

518 Lastly, users can set the sampling design for the serological survey by indicating the  
519 timepoints, individuals and biomarkers to sample from with the `observation_times` input.  
520 `observation_times` is a tibble of observation times and biomarkers for each individual. If  
521 `observation_times` is not specified within **runserosim** then the simulation will observe  
522 quantities of all biomarkers for all individuals at all time steps. For this example, we sample all  
523 individuals at the end of the simulation (t=120) for biomarker one (IgG antibody titer).

524

## 525 **2 Results**


526 Once all arguments have been defined (S1 Table), **runserosim** is ready to go and  
527 produce its 6 main outputs (S2 Table). Lastly, users can use available functions to visualize the  
528 generated outputs (S3 Table). Here, we have displayed 4 of the **runserosim** outputs for our  
529 example simulation (Figs 4 and 5).

530


531

532

533



534  
535 **Fig 4. Individual exposure probabilities and individual exposure history plots from a simulation with**  
536 **two exposure types.** The left hand plot displays the probability of successful (immunity-boosting) exposure  
537 for a simulation with 120 time steps, two exposure events and 100 individuals. The right hand plot displays  
538 the exposure histories for the same simulation. Exposure event one (top row) represents an infection event  
539 and exposure event two (bottom row) represents a vaccination event. NA indicates that an individual was  
540 not available to be exposed in that time period, usually because they were not yet born or entered the  
541 population.  
542




543  
544 **Fig 5. True and observed biomarker quantity plots.** The left hand plot displays the true antibody kinetics  
545 for a simulation with 120 time steps, one biomarker and 100 individuals. This plot displays all 100 individuals  
546 true biomarker quantities for all time steps. The right hand plot displays the observed biomarker quantity at  
547 the observation time ( $t=120$ ) given the specified observation model. In this example, all individuals alive  
548 during the endpoint ( $t=120$ ) had their biomarker quantity, in this case antibody titer, measured with a  
549 continuous assay with user-specified noise, sensitivity and specificity. The left hand plot represents the  
550 unobserved process level within *serosim* generated by the exposure, immunity and antibody models while  
551 the right hand plot represents the observed data generated by the observation model (Fig 1). The true  
552 antibody kinetics for each individual (left hand plot) is not known in real world settings where researchers  
553 only have cross-sectional antibody titers (right hand plot).

554  
555  
556  
557  
558  
559  
560  
561  
562  
563

## 564 **2.1 Case studies**

565           The *serosim* package contains two example case study vignettes to illustrate how to use  
566 *serosim* and how to structure the required inputs for **runserosim**. Case study 1 provides an  
567 example of a longitudinal singular biomarker serological survey simulation structured around  
568 measles, a one-pathogen system with vaccination, but also applicable to other vaccine  
569 preventable diseases. Case study 2 provides an example of a cross-sectional multi-biomarker  
570 serological survey structured around diphtheria and pertussis, a two-pathogen system with  
571 bivalent vaccination, but also applicable to multi-pathogen systems with multivalent vaccines.  
572 Figure 6 provides run times for simulations of varying complexity by adjusting the number of  
573 individuals for the README example and 2 case studies. *serosim* is not limited to either of these  
574 scenarios and we hope it will have applications in other systems including wildlife  
575 pathogens[20,36].

576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588




**Fig 6. runserosim run times for simulations of varying complexities.** We ran the `runserosim` function 100 times and report the mean and range of run times under various simulation settings (number of individuals and time steps). All three of these example cases are included in *serosim*. As you move to the right, model complexity increases so that case study 2 uses more computationally complex exposure, immunity, antibody, and observation models than the README example. Case study 1 is similar to the README in the number of exposure events and biomarkers but uses more realistic and complex exposure, immunity, antibody and observation models. The increase in run time between case study 1 and case study 2 is due to a computationally complex exposure model which modifies each individual's force of exposure based on their age and nutritional status.

## 2.2 Sensitivity and specificity for varying thresholds of seropositivity

Lastly, we briefly explore the sensitivity and specificity of various seropositivity thresholds within the context of case study one. The seropositivity threshold is commonly used to separate seropositive and therefore immune individuals from seronegative individuals who might be susceptible. This threshold is typically set by the assay manufacturer but can also be adjusted by the user to conduct more specific and sensitive analyses.

Since each individual's exposure history is known in *serosim*, we can assess the sensitivity and specificity tradeoffs between assigning different thresholds for seropositivity. We ran case study one (based on measles) which simulates 100 individuals across 120 time steps 100 times and examined the sensitivity and specificity of varying measles thresholds of seropositivity ranging from 100 milli-international units per milliliter (mIU/mL) (the lower limit of detection of the ELISA assay with which case study one was structured around) to 350 mIU/mL (Fig 7). Sensitivity remains at 99.56% while specificity increases from 83.68% at 100 mIU/mL to 99.95% at 350 mIU/mL (Fig 7). In this scenario, sensitivity remains high because of the large quantity of true positives and low number of false negatives as a result of the 99.6% reported assay sensitivity, the fact that there isn't much noise attributed to the antibody measurement step and ultimately that biomarker boosts due to vaccination and natural infection is high. In a system with more noise and lower assay sensitivity or exposure events with smaller biomarker boosts or faster waning rates, we would expect more variation in the sensitivity of different seropositivity thresholds. This example demonstrates how *serosim* can be used to assess the accuracy of classification criteria based on limited observations when the true latent state of the system is known and to explore the impact of epidemiological context and within-host processes on diagnostic performance.



**Fig 7. Sensitivity and specificity for varying thresholds of seropositivity in simulation-recovery experiments.** We simulated case study one 100 times and stored individual exposure history and observed biomarker quantities. We then calculated the number of true positives, true negatives, false positives and false negatives for identifying infections using various titer thresholds for seropositivity ranging from 100 mIU/mL to 350 mIU/mL. Here, we plotted the sensitivity and specificity achieved at each of those titer thresholds.

## Conclusion, limitations and future directions

The *serosim* package was designed to simulate serological data under different survey designs and underlying immunoepidemiological processes while also providing a systematic framework for validating inference methods. Many epidemiological studies using serological data rely on pre-defined definitions of seroconversion, seropositivity or antibody kinetics to draw inferences about the underlying epidemiology of a pathogen[37]. However, such studies often use real-world datasets without first considering the biases that may arise when the fitted model differs substantially from the true data-generating process. Simulation studies are useful for identifying the limitations, biases and accuracies arising from sample variability, misspecified models or neglected variables[16,38–40]. *serosim* is a generalized approach to this problem, allowing researchers to simulate serological data representing a disease system of interest by explicitly specifying the within-host processes, patterns of infection and vaccination, population demography and other factors which determine observed biomarker quantities. By generating simulations within a single framework, we anticipate better generalization and comparison of methods between pathogen systems and serologic assays[1,14,41].

A key use case for *serosim* is for researchers and public health officials to improve serological survey design. We envision that *serosim* can be used to simulate datasets with different sample sizes, spatial distribution of samples, and sampling frequencies, providing a tool for power calculations. There are a number of existing frameworks for evaluating survey designs based on seroprevalence estimates, taking into account both the contribution of imperfect sensitivity, specificity and model variability to parameter estimation uncertainty[16,42]. However, few tools explicitly consider the full complexity of the underlying biology and epidemiology which determine an observed sample of antibody titers[40]. By separating each step of this generative process into distinct modules, *serosim* requires users to account for sources of measurement error, variation and bias that cause deviation from the underlying parameters of interest. With this



generative model in place, inference models (e.g., estimating force of infection using a serocatalytic model [12] or estimating time-since-infection using antibody waning estimates[35]) can be applied to simulated datasets of different sizes and sampling designs to assess their power in recovering ground-truth parameters. These so-called “simulation-recovery” experiments are especially useful as the model being fitted will be, by definition, a misspecified version of the true generative model (with parallels to statistical model misspecification [43]). Designing studies using these simulated datasets also provides interim data with which researchers can develop their inference methods as data collection progresses.

Although we have structured the *serosim* model and code in a flexible, generalized framework, there are limitations to its ease of application to some systems. Some parts of the generative process are very poorly understood for some pathogens (e.g., correlates of protection for the immunity model may be complex[44]; the relationship between time-since-infection and multiple biomarker quantities may be highly variable[45]), and the relationships between exposure and measurements of some modern multiplex serological assays are not yet precisely characterized[25]. We have included a range of ready-to-use functions to encompass various epidemiological and immunological contexts here (S4-8 Tables), however, this is not an exhaustive list as we encourage users to construct new model inputs to match their desired system (e.g., constructing their own antibody kinetics model). There is also a trade-off between framework flexibility and computational speed. Structuring *serosim* as distinct modules places responsibility on the user to ensure that custom code is fast enough to not substantially bottleneck the simulation, particularly for systems with a large number of exposure types, biomarkers, or individuals. However, given that *serosim* is not intended for integration in multi-iteration code (e.g., nested within a Markov chain Monte Carlo algorithm), speed is unlikely to be an issue for most use cases.

Part of the motivation behind *serosim* is to support the rise in development of complex models relying on quantitative antibody measurements as opposed to simple binary serostatus data. These models explicitly describe the relationship between antibody titer and time-since-infection, often estimated using longitudinal data, and then use this relationship to back-calculate seroincidence from cross-sectional data [13,14,35,46–48]. Although underpinned by similar principles, such approaches are usually tailored to a particular pathogen system. By encouraging researchers to be explicit about the generative process common to many settings, we hope to facilitate the sharing and standardization of these more advanced sero-epidemiologic methods.

## **Data availability**

All code, tutorials and documentation are made freely available under the GNU General Public License at <https://github.com/AMenezes97/serosim>. Commit 65c7163 was used at the time of submission.

## **Acknowledgments**

Figures 1-3 and S1 Fig were created with BioRender.com.

## **Financial support**

CJEM was supported by a Bill and Melinda Gates Foundation grant (INV-016091). CJEM gratefully acknowledges financial support from the Schmidt DataX Fund at Princeton University made possible through a major gift from the Schmidt Futures Foundation. JAH is funded by a Wellcome Trust Early Career Award (225001/Z/22/Z).

## **Conflict of interest**

The authors have no conflicts of interest to report.

## References

1. Metcalf CJE, Farrar J, Cutts FT, Basta NE, Graham AL, Lessler J, et al. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. *Lancet*. 2016;388: 728–730.
2. Takahashi S, Metcalf CJE, Ferrari MJ, Moss WJ, Truelove SA, Tatem AJ, et al. Reduced vaccination and the risk of measles and other childhood infections post-Ebola. *Science*. 2015;347: 1240–1242.
3. Bjørnstad ON, Finkenstädt BF, Grenfell BT. Dynamics of Measles Epidemics: Estimating Scaling of Transmission Rates Using a Time Series SIR Model. *Ecol Monogr*. 2002;72: 169–184.
4. Lessler J, Metcalf CJE, Grais RF, Luquero FJ, Cummings DAT, Grenfell BT. Measuring the performance of vaccination programs using cross-sectional surveys: a likelihood framework and retrospective analysis. *PLoS Med*. 2011;8: e1001110.
5. Cutts FT, Izurieta HS, Rhoda DA. Measuring coverage in MNCH: design, implementation, and interpretation challenges associated with tracking vaccination coverage using household surveys. *PLoS Med*. 2013;10: e1001404.
6. Winter AK, Martinez ME, Cutts FT, Moss WJ, Ferrari MJ, McKee A, et al. Benefits and Challenges in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination. *J Infect Dis*. 2018;218: 355–364.
7. Murray CJL, Shengelia B, Gupta N, Moussavi S, Tandon A, Thieren M. Validity of reported vaccination coverage in 45 countries. *Lancet*. 2003;362: 1022–1027.
8. Clapham H, Hay J, Routledge I, Takahashi S, Choisy M, Cummings D, et al. Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity. *Emerg Infect Dis*. 2020;26: 1978–1986.
9. Cucunubá ZM, Nouvellet P, Conteh L, Vera MJ, Angulo VM, Dib JC, et al. Modelling historical changes in the force-of-infection of Chagas disease to inform control and elimination programmes: application in Colombia. *BMJ Glob Health*. 2017;2: e000345.
10. Winter AK, Wesolowski AP, Mensah KJ, Ramamonjiharisoa MB, Randriamanantena AH, Razafindratsimandresy R, et al. Revealing Measles Outbreak Risk With a Nested Immunoglobulin G Serosurvey in Madagascar. *Am J Epidemiol*. 2018;187: 2219–2226.
11. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. *N Engl J Med*. 2007;357: 1903–1915.
12. Hens N, Aerts M, Faes C, Shkedy Z, Lejeune O, Van Damme P, et al. Seventy-five years of estimating the force of infection from current status data. *Epidemiol Infect*. 2010;138: 802–812.
13. Salje H, Cummings DAT, Rodriguez-Barraquer I, Katzelnick LC, Lessler J, Klungthong C, et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. *Nature*. 2018;557: 719–723.

14. Pepin KM, Kay SL, Golas BD, Shriner SS, Gilbert AT, Miller RS, et al. Inferring infection hazard in wildlife populations by linking data across individual and population scales. *Ecol Lett.* 2017;20: 275–292.
15. Hay JA, Minter A, Ainslie KEC, Lessler J, Yang B, Cummings DAT, et al. An open source tool to infer epidemiological and immunological dynamics from serological data: serosolver. *PLoS Comput Biol.* 2020;16: e1007840.
16. Larremore DB, Fosdick BK, Bubar KM, Zhang S, Kissler SM, Metcalf CJE, et al. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. *Elife.* 2021;10. doi:10.7554/eLife.64206
17. Pothin E, Ferguson NM, Drakeley CJ, Ghani AC. Estimating malaria transmission intensity from *Plasmodium falciparum* serological data using antibody density models. *Malar J.* 2016;15: 79.
18. Salje H, Cauchemez S, Alera MT, Rodriguez-Barraquer I, Thaisomboonsuk B, Srikiatkachorn A, et al. Reconstruction of 60 Years of Chikungunya Epidemiology in the Philippines Demonstrates Episodic and Focal Transmission. *J Infect Dis.* 2016;213: 604–610.
19. Rydevik G, Innocent GT, Marion G, Davidson RS, White PCL, Billinis C, et al. Using Combined Diagnostic Test Results to Hindcast Trends of Infection from Cross-Sectional Data. *PLoS Comput Biol.* 2016;12: e1004901.
20. Borremans B, Hens N, Beutels P, Leirs H, Reijnders J. Estimating Time of Infection Using Prior Serological and Individual Information Can Greatly Improve Incidence Estimation of Human and Wildlife Infections. *PLoS Comput Biol.* 2016;12: e1004882.
21. Teunis PFM, van Eijkeren JCH, Ang CW, van Duynhoven YTHP, Simonsen JB, Strid MA, et al. Biomarker dynamics: estimating infection rates from serological data. *Stat Med.* 2012;31: 2240–2248.
22. Matsuzawa Y, Iwatsuki-Horimoto K, Nishimoto Y, Abe Y, Fukuyama S, Hamabata T, et al. Antigenic Change in Human Influenza A(H2N2) Viruses Detected by Using Human Plasma from Aged and Younger Adult Individuals. *Viruses.* 2019;11. doi:10.3390/v11110978
23. Shrock E, Fujimura E, Kula T, Timms RT, Lee I-H, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. *Science.* 2020;370. doi:10.1126/science.abd4250
24. Razafimahatratra SL, Menezes A, Wesolowski A, Rafetrarivony L, Cauchemez S, Razafindratsimandresy R, et al. Leveraging serology to titrate immunisation programme functionality for diphtheria in Madagascar. *Epidemiology & Infection.* 2022;150. doi:10.1017/S0950268822000097
25. Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. *Science.* 2019;366: 599–606.
26. Wickham H, Navarro D, Pedersen TL. *ggplot2: Elegant Graphics for Data Analysis*; 2009.

27. Dowle, Srinivasan, Short. data. table: Extension of “data. frame.” R package version.
28. Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al. Welcome to the tidyverse. *J Open Source Softw.* 2019;4: 1686.
29. Pedersen TL. Package “patchwork.” R package <http://CRAN.R-project.org/package=patchwork> Cran. 2019. Available: <ftp://ftp.onet.pl/pub/mirrors/CRAN/web/packages/patchwork/patchwork.pdf>
30. Wickham H. reshape2: flexibly reshape data: a reboot of the reshape package. R package version.
31. Wickham KMA. tibble: Simple Data Frames. 2022. Available: <https://CRAN.R-project.org/package=tibble>
32. Le D, Miller JD, Ganusov VV. Mathematical modeling provides kinetic details of the human immune response to vaccination. *Front Cell Infect Microbiol.* 2014;4: 177.
33. White MT, Griffin JT, Akpogheneta O, Conway DJ, Koram KA, Riley EM, et al. Dynamics of the antibody response to Plasmodium falciparum infection in African children. *J Infect Dis.* 2014;210: 1115–1122.
34. Andraud M, Lejeune O, Musoro JZ, Ogunjimi B, Beutels P, Hens N. Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis a virus. *PLoS Comput Biol.* 2012;8: e1002418.
35. Simonsen J, Mølbak K, Falkenhorst G, Krogfelt KA, Linneberg A, Teunis PFM. Estimation of incidences of infectious diseases based on antibody measurements. *Stat Med.* 2009;28: 1882–1895.
36. Prager KC, Buhnerkempe MG, Greig DJ, Orr AJ, Jensen ED, Gomez F, et al. Linking longitudinal and cross-sectional biomarker data to understand host-pathogen dynamics: Leptospira in California sea lions (Zalophus californianus) as a case study. *PLoS Negl Trop Dis.* 2020;14: e0008407.
37. Hens N, Shkedy Z, Aerts M, Faes C, Van Damme P, Beutels P. Modeling Infectious Disease Parameters Based on Serological and Social Contact Data: A Modern Statistical Perspective. Springer; 2014.
38. Gamble A, Garnier R, Chambert T, Gimenez O, Boulinier T. Next-generation serology: integrating cross-sectional and capture-recapture approaches to infer disease dynamics. *Ecology.* 2020;101: e02923.
39. Wu KM, Riley S. Simulation-guided design of serological surveys of the cumulative incidence of influenza infection. *BMC Infect Dis.* 2014;14: 505.
40. Vinh DN, Boni MF. Statistical identifiability and sample size calculations for serial seroepidemiology. *Epidemics.* 2015;12: 30–39.
41. Mina MJ, Metcalf CJE, McDermott AB, Douek DC, Farrar J, Grenfell BT. A global Immunological observatory to meet a time of pandemics. *Elife.* 2020;9: 1–5.
42. Blaizot S, Herzog SA, Abrams S, Theeten H, Litzroth A, Hens N. Sample size calculation

for estimating key epidemiological parameters using serological data and mathematical modelling. *BMC Med Res Methodol.* 2019;19: 51.

43. Sivula T, Magnusson M, Matamoros AA, Vehtari A. Uncertainty in Bayesian Leave-One-Out Cross-Validation Based Model Comparison. 2020 [cited 24 Nov 2022]. doi:10.48550/arXiv.2008.10296
44. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med.* 2021;27: 2032–2040.
45. Helb DA, Tetteh KKA, Felgner PL, Skinner J, Hubbard A, Arinaitwe E, et al. Novel serologic biomarkers provide accurate estimates of recent *Plasmodium falciparum* exposure for individuals and communities. *Proc Natl Acad Sci U S A.* 2015;112: E4438–47.
46. Pelleau S, Woudenberg T, Rosado J, Donnadieu F, Garcia L, Obadia T, et al. Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection. *J Infect Dis.* 2021;224: 1489–1499.
47. Kucharski AJ, Lessler J, Cummings DAT, Riley S. Timescales of influenza A/H3N2 antibody dynamics. *PLoS Biol.* 2018;16: e2004974.
48. Tsang TK, Perera RAPM, Fang VJ, Wong JY, Shiu EY, So HC, et al. Reconstructing antibody dynamics to estimate the risk of influenza virus infection. *Nat Commun.* 2022;13: 1557.